Q3 2024 Holdings
Filed 2024-11-14 | 55 holdings | $926.8M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $66.5M | 2,100,000 | 7.2% |
| Structure Therapeutics Inc(GPCR) | SPONSORED ADS | 86366E106 | $54.9M | 1,250,000 | 5.9% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $54.4M | 1,200,000 | 5.9% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $45.9M | 935,000 | 5.0% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $45.4M | 1,000,000 | 4.9% |
| Olema Pharmaceuticals Inc(OLMA) | COM | 68062P106 | $38.3M | 3,208,875 | 4.1% |
| Vaxcyte Inc(PCVX) | COM | 92243G108 | $34.3M | 300,000 | 3.7% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $31.4M | 1,100,000 | 3.4% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $30.6M | 900,000 | 3.3% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $30.5M | 3,500,000 | 3.3% |
| Ionis Pharmaceuticals Inc(IONS) | COM | 462222100 | $30.0M | 750,000 | 3.2% |
| Erasca Inc(ERAS) | COM | 29479A108 | $29.8M | 10,900,000 | 3.2% |
| Apellis Pharmaceuticals Inc(APLS)Call | COM | 03753U106 | $28.8M | 1,000,000 | 3.1% |
| Merus N V | COM | N5749R100 | $28.7M | 575,000 | 3.1% |
| Galapagos NV(GLPG) | SPON ADR | 36315X101 | $23.0M | 800,000 | 2.5% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $23.0M | 800,000 | 2.5% |
| Design Therapeutics Inc(DSGN) | COM | 25056L103 | $22.7M | 4,217,627 | 2.4% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $22.1M | 500,000 | 2.4% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $21.6M | 2,000,000 | 2.3% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $21.1M | 400,000 | 2.3% |
| Bicara Therapeutics Inc(BCAX) | COM | 055477103 | $20.4M | 800,000 | 2.2% |
| Sarepta Therapeutics Inc(SRPT) | COM | 803607100 | $18.7M | 150,000 | 2.0% |
| Annexon Inc(ANNX) | COM | 03589W102 | $15.4M | 2,600,000 | 1.7% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $15.4M | 1,100,000 | 1.7% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $12.6M | 495,000 | 1.4% |
| Beam Therapeutics Inc(BEAM) | COM | 07373V105 | $12.3M | 500,000 | 1.3% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $12.0M | 450,000 | 1.3% |
| Bicycle Therapeutics PLC(BCYC) | SPONSORED ADS | 088786108 | $11.3M | 500,000 | 1.2% |
| Y-Mabs Therapeutics Inc(YMABUSD) | COM | 984241109 | $10.5M | 800,000 | 1.1% |
| Arvinas Inc(ARVN) | COM | 04335A105 | $9.9M | 400,000 | 1.1% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $9.2M | 2,750,000 | 1.0% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $7.7M | 75,000 | 0.8% |
| Compass Pathways PLC(CMPS) | SPONSORED ADS | 20451W101 | $7.3M | 1,159,030 | 0.8% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $6.3M | 257,330 | 0.7% |
| Rocket Pharmaceuticals Inc(RCKT) | COM | 77313F106 | $6.0M | 325,000 | 0.6% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $5.9M | 200,000 | 0.6% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $5.7M | 160,000 | 0.6% |
| Astria Therapeutics Inc(CATBUSD) | COM | 04635X102 | $5.5M | 500,000 | 0.6% |
| Fulcrum Therapeutics Inc(FULC)Call | COM | 359616109 | $5.4M | 1,500,000 | 0.6% |
| Cybin Inc(HELP) | COM NEW | 23256X407 | $5.3M | 600,000 | 0.6% |
| Engene Holdings Inc(ENGN) | COM | 29286M105 | $5.3M | 800,000 | 0.6% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $5.1M | 539,079 | 0.6% |
| Lineage Cell Therapeutics in(LCTX) | COM | 53566P109 | $4.5M | 5,000,000 | 0.5% |
| Rapport Therapeutics Inc(RAPP) | COM | 75383L102 | $4.1M | 208,910 | 0.4% |
| Silence Therapeutics PLC(SLN) | ADS | 82686Q101 | $3.6M | 200,000 | 0.4% |
| Atyr Pharma Inc(ATYR) | COM NEW | 002120202 | $3.5M | 2,000,000 | 0.4% |
| Nextcure Inc | COM | 65343E108 | $3.4M | 2,500,000 | 0.4% |
| Adverum Biotechnologies Inc(AVU0) | COM NEW | 00773U207 | $2.9M | 416,666 | 0.3% |
| Artiva Biotherapeutics Inc(ARTV) | COM | 04317A107 | $2.1M | 145,089 | 0.2% |
| Unicycive Therapeutics Inc | COM | 90466Y103 | $2.1M | 5,078,927 | 0.2% |